APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.

Amid an outpouring of frustration with for-profit health insurance sparked by the assassination of UnitedHealthcare CEO Brian ...

Wall Street analysts who follow Viking and Summit expect further gains in 2025. Quick gains are often lost on Wall Street, ...

Ervebo’s impact extends beyond Ebola, offering a potential model for tackling other infectious disease outbreaks, such as ...